Proteomic analysis of rat prefrontal cortex after chronic valproate treatment
Article first published online: 1 APR 2014
Copyright © 2014 Wiley Periodicals, Inc.
Journal of Neuroscience Research
Volume 92, Issue 7, pages 927–936, July 2014
How to Cite
Thangavel, M., Seelan, R. S., Lakshmanan, J., Vadnal, R. E., Stagner, J. I., Parthasarathy, L. K., Casanova, M. F., El-Mallakh, R. S. and Parthasarathy, R. N. (2014), Proteomic analysis of rat prefrontal cortex after chronic valproate treatment. J. Neurosci. Res., 92: 927–936. doi: 10.1002/jnr.23373
- Issue published online: 13 MAY 2014
- Article first published online: 1 APR 2014
- Manuscript Revised: 28 JAN 2014
- Manuscript Accepted: 28 JAN 2014
- Manuscript Received: 17 OCT 2013
- Office of Research and Development, Medical Research Service, Department of Veterans Affairs
- bipolar disorder;
- prefrontal cortex;
Valproic acid (VPA) is commonly used to treat bipolar disorder (BD), but its therapeutic role has not been clearly elucidated. To gain insights into VPA's mechanism of action, proteomic analysis was used to identify differentially expressed proteins in the rat prefrontal cortex (PFC), a region particularly affected in BD, after 6 weeks of VPA treatment. Proteins from PFCs of control and VPA-treated rats were separated by 2D-DIGE and identified by mass spectrometry. Among the 2,826 protein spots resolved, the abundance of 19 proteins was found to be significantly altered in the VPA-treated group (with the levels of three proteins increasing and 16 decreasing). Seven proteins whose levels were significantly altered after chronic VPA exposure were quantified by Western blot analysis. The 19 identified proteins represent potential new targets for VPA action and should aid in our understanding of the role of VPA in BD. © 2014 Wiley Periodicals, Inc.